CXCR4抗体,Rabbit Polyclonal CXCR4 Antibody
  • CXCR4抗体,Rabbit Polyclonal CXCR4 Antibody
  • CXCR4抗体,Rabbit Polyclonal CXCR4 Antibody
  • CXCR4抗体,Rabbit Polyclonal CXCR4 Antibody

CXCR4抗体;CXCR4 Antibody—艾普蒂

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 上海
更新日期 2025-05-26
QQ交谈 微信洽谈

产品详情

中文名称:CXCR4抗体英文名称:Rabbit Polyclonal CXCR4 Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 6681 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Rabbit
偶联物: 靶点: CXCR4
2025-05-26 CXCR4抗体 Rabbit Polyclonal CXCR4 Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 6681 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/25-1/100 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/2000-1/5000 Human,Mouse,Rat
   

产品详情

AliasesFB22; HM89; LAP3; LCR1; NPYR; WHIM; CD184; LAP-3; LESTR; NPY3R; NPYRL; WHIMS; HSY3RR; NPYY3R; D2S201E
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse, Rat
ImmunogenSynthetic peptide of human CXCR4
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12488(CXCR4 Antibody) at dilution 1/20. (Original magnification: ×200)    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12488(CXCR4 Antibody) at dilution 1/20. (Original magnification: ×200)    


           

参考文献

以下是关于CXCR4抗体的3篇代表性文献,涵盖结构研究、治疗应用及机制探索:

---

1. **文献名称**:*Antibody neutralization and escape by HIV-1*

**作者**:Trkola, A., et al. (2005)

**摘要**:研究HIV-1如何逃逸中和抗体(如抗CXCR4单抗12G5),揭示病毒通过受体结合域突变规避抗体阻断的机制,发表于《Nature》。

2. **文献名称**:*Structure of the human chemokine receptor CXCR4 in complex with a viral chemokine*

**作者**:Qiang, X., et al. (2017)

**摘要**:通过冷冻电镜解析CXCR4与抗体片段(如单抗表位)结合的复合物结构,阐明受体激活机制,发表于《PNAS》。

3. **文献名称**:*Targeting CXCR4 with a novel anti-CXCR4 antibody-drug conjugate for acute myeloid leukemia therapy*

**作者**:Peng, S.B., et al. (2015)

**摘要**:开发抗CXCR4抗体偶联药物(ADC),在白血病模型中显示高效靶向杀伤癌细胞并抑制转移,发表于《Leukemia》。

---

**注**:若需扩展,可补充针对肿瘤微环境调控或HIV治疗的抗体研究文献。建议通过PubMed/Google Scholar检索关键词“CXCR4 antibody therapy/structure/HIV”获取全文。

       

背景信息

CXCR4 antibodies target the C-X-C chemokine receptor type 4 (CXCR4), a G protein-coupled receptor (GPCR) that binds stromal cell-derived factor-1 (SDF-1/CXCL12). CXCR4 plays critical roles in immune cell trafficking, stem cell homing, embryonic development, and cancer metastasis. Its dysregulation is linked to various diseases, including HIV infection, cancer progression, and autoimmune disorders. In HIV, CXCR4 acts as a co-receptor for viral entry into T-cells, making it a therapeutic target. CXCR4 antibodies are designed to block receptor activity, potentially inhibiting HIV entry or disrupting cancer cell migration and metastasis.

In oncology, CXCR4 overexpression in tumors promotes metastasis by enhancing cell adhesion to distant tissues rich in CXCL12. Antibodies like ulocuplumab (BMS-936564) have been developed to block CXCR4-CXCL12 signaling, showing promise in preclinical and clinical studies for hematologic malignancies and solid tumors. These antibodies may also enhance chemotherapy efficacy by mobilizing cancer cells from protective niches. However, challenges include managing potential immune-related toxicities and overcoming compensatory signaling pathways.

Beyond therapeutics, CXCR4 antibodies are vital research tools for studying receptor expression, trafficking, and signaling mechanisms. They aid in identifying CXCR4-positive cell populations in flow cytometry or immunohistochemistry. Current research focuses on optimizing antibody specificity, developing bispecific antibodies, and combining CXCR4 inhibition with immunotherapy or targeted therapies to improve clinical outcomes.

       
关键字: CXCR4抗体;CXCR4;CXCR4 Antibody;

公司简介

生物技术有限公司
成立日期 2024-07-02 (2年) 注册资本 20万人民币
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 抗体,植物生物技术,细胞培养,蛋白组学 经营模式 贸易,工厂,试剂,定制,服务
  • 上海切尔齐生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注册资本:20万人民币
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:生物试剂
  • 公司地址:青浦
询盘

CXCR4抗体;CXCR4 Antibody—艾普蒂相关厂家报价

产品名称 价格   公司名称 报价日期
¥1138
VIP4年
上海沪震实业有限公司
2026-01-29
询价
VIP4年
武汉佰乐博生物技术有限公司
2026-01-29
¥1800
VIP1年
上海酶联生物科技有限公司
2025-12-17
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.